Fresenius agrees USD4.75bn deal for Akorn

25 April 2017 - Deborah Wilkes

Archived

German healthcare company Fresenius has agreed to acquire US generics, OTC and animal health company Akorn in a deal worth approximately USD4.75 billion, including debt.

Annual Subscription Holder?

Sign in to continue reading.
 

Sign In

Back to Industry News

Share this page: